Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial.

[1]  A. Hauschild,et al.  Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma , 2016, The oncologist.

[2]  R. Dummer,et al.  The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma. , 2016, Journal of the American Academy of Dermatology.

[3]  A. Henry,et al.  Increased Risk of Cutaneous Squamous Cell Carcinoma After Vismodegib Therapy for Basal Cell Carcinoma. , 2016, JAMA dermatology.

[4]  A. Hauschild,et al.  Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial. , 2015, The Lancet. Oncology.

[5]  A. Hauschild,et al.  Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC. , 2015, Journal of the American Academy of Dermatology.

[6]  L. Mortier,et al.  Persistent alopecia induced by vismodegib , 2015, The British journal of dermatology.

[7]  T. Olencki,et al.  Determination of locally advanced basal cell carcinoma (BCC) in the first 285 patients enrolled in the RegiSONIC disease registry study. , 2015 .

[8]  P. Ascierto,et al.  Identifying locally advanced basal cell carcinoma eligible for treatment with vismodegib: an expert panel consensus. , 2015, Future oncology.

[9]  P. Dziewulski,et al.  Challenges and new horizons in the management of advanced basal cell carcinoma: a UK perspective , 2014, British Journal of Cancer.

[10]  Christopher J. Miller,et al.  Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: Final update (30-month) of the pivotal ERIVANCE BCC study. , 2014 .

[11]  A. Hauschild,et al.  Metastatic basal cell carcinoma: prognosis dependent on anatomic site and spread of disease. , 2014, European journal of cancer.

[12]  A. Chang,et al.  Advanced Basal Cell Carcinoma: Epidemiology and Therapeutic Innovations , 2014, Current Dermatology Reports.

[13]  L. Arends,et al.  Risk of subsequent cutaneous malignancy in patients with prior keratinocyte carcinoma: a systematic review and meta-analysis. , 2013, European journal of cancer.

[14]  A. Wysong,et al.  New onset of keratoacanthomas after vismodegib treatment for locally advanced basal cell carcinomas: a report of 2 cases. , 2013, JAMA dermatology.

[15]  Aleksandar Sekulic,et al.  Efficacy and safety of vismodegib in advanced basal-cell carcinoma. , 2012, The New England journal of medicine.

[16]  E. Epstein.  Basal cell carcinomas: attack of the hedgehog , 2008, Nature Reviews Cancer.

[17]  R. Stern,et al.  Risk of developing a subsequent nonmelanoma skin cancer in patients with a history of nonmelanoma skin cancer: a critical review of the literature and meta-analysis. , 2000, Archives of dermatology.

[18]  R. Plummer,et al.  Managing adverse events associated with vismodegib in the treatment of basal cell carcinoma. , 2017, Future oncology.

[19]  Désirée Ratner,et al.  Current concepts : Basal-cell carcinoma , 2005 .

[20]  D. Kuijpers,et al.  Basal Cell Carcinoma , 2002, American journal of clinical dermatology.